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Abstract
Development of vaccines in autoimmune diseases has received wide attention over the last decade. However, many
vaccines showed limited clinical efficacy. To enhance vaccine efficacy in infectious diseases, biocompatible and
biodegradable polymeric nanoparticles have gained interest as antigen delivery systems. We investigated in mice whether
antigen-encapsulated PLGA (poly-lactic-co-glycolic acid), PLGA-TMC (N-trimethyl chitosan) or TMC-TPP (tri-polyphosphate)
nanoparticles can also be used to modulate the immunological outcome after nasal vaccination. These three nanoparticles
enhanced the antigen presentation by dendritic cells, as shown by increased in vitro and in vivo CD4+ T-cell proliferation.
However, only nasal PLGA nanoparticles were found to induce an immunoregulatory response as shown by enhanced
Foxp3 expression in the nasopharynx associated lymphoid tissue and cervical lymph nodes. Nasal administration of OVA-
containing PLGA particle resulted in functional suppression of an OVA-specific Th-1 mediated delayed-type hypersensitivity
reaction, while TMC-TPP nanoparticles induced humoral immunity, which coincided with the enhanced generation of OVA-
specific B-cells in the cervical lymph nodes. Intranasal treatment with Hsp70-mB29a peptide-loaded PLGA nanoparticles
suppressed proteoglycan-induced arthritis, leading to a significant reduction of disease. We have uncovered a role for PLGA
nanoparticles to enhance CD4+ T-cell mediated immunomodulation after nasal application. The exploitation of this
differential regulation of nanoparticles to modulate nasal immune responses can lead to innovative vaccine development
for prophylactic or therapeutic vaccination in infectious or autoimmune diseases.
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Introduction
Nasal vaccination is described for the prevention of infectious
diseases such as hepatitis B [1,2] or influenza [3,4]. However,
recently, nasal antigen application has also become of interest as a
route of vaccination in the field of autoimmunity [5–9] and allergy
[10,11]. Similar to other forms of mucosal immunization, nasal
antigen application can stimulate antigen-specific responses locally
and in the peripheral mucosal tissues [12–15]. Vaccination via the
nasal mucosa might be preferred over oral vaccination given the
low proteolytic activity in the nasal mucosa; this route of
immunization requires a lower dose of antigen than that of oral
immunization, which might also reduce the change of producing
negative side-effects [16]. The immune response induced following
mucosal antigen application depends on many factors, such as the
nature of the antigen (soluble versus particulate), antigen dose, size
and delivery to the mucosal tissues [16]. Although the immune
response that is induced following mucosal antigen application
depends on the antigen that is used, nanoparticle characteristics
might also play an important role. For tolerance induction to self
antigens used for vaccination in autoimmune diseases one would
prefer to combine a self antigen with a vaccine that favors
tolerance induction. On the other hand, in the case of prevention
of infectious diseases an immunogenic antigen with a vaccine that
enhances humoral immunity is preferred. Therefore, rational
future vaccine design might benefit from knowledge of immuno-
modulatory characteristics of nanoparticles. In recent years,
several in vivo studies have been conducted to investigate
nanoparticle-mediated delivery of antigen at mucosal sites.
Nanoparticles are available as non-toxic delivery systems with
promise for nasal vaccination [17–20]. Since mucosal antigen
application elicits different immune responses such as T-helper 2
(TH2)-mediated humoral immunity or T-helper 1 (TH1)-mediat-
ed Delayed-Type Hypersensitivity (DTH) [21–23], we explored if
nanoparticles can differentially modulate the outcome of nasal
vaccination. The readout to evaluate the efficacy of the applied
vaccine relies mostly on induction of humoral immune responses
as indicated by increased antigen-specific antibody titers [4,18,24].
However, this does not give insight into the underlying
immunological mechanisms that drive the response towards
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Figure 1. Nanoparticle mediated enhanced antigen presentation capacity of BMDCs in vitro. BMDC were incubated in the presence of
sOVA-FITC or OVA-FITC encapsulated into PLGA, PLGA-TMC or TMC-TPP nanoparticles at different concentrations. External FITC signaling was
silenced by trypan blue. A. The DMFI of OVA-FITC was assessed by subtraction of FITC signaling at 4uC from 37uC. B. OVA-FITC uptake by BMDC
shown as the net percentage of OVA-FITC positive cells. C. CFSE-labeled CD4+ T-cells were incubated with BMDC stimulated with sOVA or OVA
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humoral immunity or DTH. Marazuela et al. previously showed
that intranasal administration of PLGA particles that contained a
peptide with the major T-cell epitope of Ole e 1 induced a
modified Th2 response and prevented mice from allergic
sensitization of the whole protein [25,26]. However, little is still
known about the role of CD4+ T-cells in nasal vaccination and
how different nanoparticle treatment might influence the activa-
tion of these cells, locally and in the peripheral tissues.
To study the mechanisms behind humoral immunity or DTH
after nasal vaccination, three polymeric nanoparticles were
analyzed that are efficient antigen delivery systems; PLGA (poly-
lactic-co-glycolic acid), PLGA-TMC (N-trimethyl chitosan) and
TMC-TPP (tri-polyphosphate) nanoparticles that all contained the
model antigen ovalbumin (OVA). These particles have a similar
average diameter of 250–500 nm, but differ in their surface charge
and antigen release kinetics [17,18].
For example, nasal application of TMC-TPP particles has been
described in the field of influenza vaccination and elicits humoral
immune responses as shown by a significant increase in antigen-
specific IgG1/IgG2a serum titers and increased sIgA titers in nasal
washes [4]. In contrast to induction of humoral immunity, mice
fed a single dose of 40 mg of type II collagen (CII)-containing
PLGA particles had reduced severity of arthritis and reduced anti-
CII-specific IgG antibody titers and CII-specific T-cell responses
[24].
We investigated in an OVA-specific DTH model whether
nanoparticles itself cause a shift in the immunological outcome
after nasal antigen application as shown by the activation and
differentiation of CD4+ T-cell responses both at the site of
vaccination and systemically. In addition, we investigated the
relevance of nanoparticle mediated mucosal tolerance after nasal
application in a proteoglycan induced arthritis (PGIA) model [27]
with heat shock protein 70 (Hsp70) peptide mB29a encapsulated
nanoparticles. Hsp70 is known to be one of the most conserved
Hsps and has been shown to have disease suppressive properties
[28–30]. Mouse Hsp70-peptide mB29a has been shown to be
immunosuppressive after nasal application in the PGIA model
[31]. Therefore, we explored the additional immunosuppressive
effect of nanoparticle treatment by encapsulating the mB29a
peptide.
This study was performed to obtain more insight into the
mechanism by which nanoparticles drive the immune response
towards immunomodulatory responses. The data may assist future
rational vaccine design for prophylactic or therapeutic vaccination
in infectious and autoimmune diseases, respectively.
Results
Differential uptake of FITC labeled OVA by BMDCs after
nanoparticle treatment
We previously showed nanoparticle differences in association
with and uptake by DCs as visualized by tracing uptake of OVA in
vitro [17,18]. These differences in association might modulate the
subsequent antigen presenting capacity of DCs.
To investigate this, we treated DCs in vitro with OVA
encapsulated in PLGA, PLGA-TMC or TMC-TPP nanoparticles
or soluble OVA (sOVA) as a control and studied phenotypic and
functional differences between treated DCs. No differences in DC
maturation or viability were observed as analyzed by CD11c,
MHC-class-II, CD40, CD86 and 7-AAD staining after nanopar-
ticle treatment at OVA concentrations varying from 1 ng/ml to
1 mg/ml. We did not detect significant differences in cytokine
profiles in culture supernatants (data not shown).
Next, we studied the uptake of OVA-FITC encapsulated in
PLGA, PLGA-TMC and TMC-TPP nanoparticles by DCs
silencing extracellular attached FITC signaling with trypan blue.
OVA-FITC association with DCs is shown as the FITC expression
(DMFI) (Figure 1A) or percentage of OVA-FITC positive cells
(Figure 1B).
OVA-FITC uptake by DCs treated with TMC-TPP was lower
compared to sOVA-FITC treatment as shown by a low FITC
DMFI expression and decreased percentage of OVA-FITC
positive cells (Figures 1A and 1B). Furthermore, compared to
sOVA, PLGA-TMC treatment enhanced the antigen uptake by
DCs even at low (25 ng/ml) OVA concentrations. Both PLGA
and PLGA-TMC treatment enhanced antigen uptake with OVA
at 0.25 mg/ml. Apart from a reduced uptake of TMC-TPP
particles we could not detect differences in antigen uptake at 1 mg/
ml between sOVA, PLGA or PLGA-TMC treatment. The latter is
being suggestive of saturated antigen uptake after 1.5 h of antigen
incubation (Figure 1B).
In sum, nanoparticle characteristics differentially affected the
antigen uptake by DCs in vitro as shown by a lower number of
OVA-FITC positive cells and DMFI when DCs encounter TMC-
TPP particles compared to PLGA and PLGA-TMC.
Nanoparticles enhance OVA-specific CD4+ T-cell
proliferation in vitro
To investigate whether the small differences in antigen uptake
by DCs could affect the antigen presenting capacity of DCs,
nanoparticle treated DCs were studied in vitro by co-culture with
OVA-specific T-cells. DCs treated with OVA encapsulated
PLGA, PLGA-TMC or TMC-TPP particles were cultured for
72 h in the presence of OVA-specific CFSE-labeled CD4+ T-cells.
The antigen presenting capacity of DCs was enhanced after
nanoparticle treatment since T-cells stimulated by particle treated
DCs showed enhanced T-cell proliferation compared to T-cells
cultured in the presence of sOVA treated DCs. Especially, PLGA
and PLGA-TMC particles strongly enhanced CD4+ T-cell
proliferation even at a low OVA concentration of 25 ng/ml
(Figure 1C). Additionally, in the culture supernatants of T-cells
stimulated in the presence of 1 mg/ml of OVA containing PLGA
or PLGA-TMC particles more IL-2 (Figure 1D), IFN-c (Figure 1E)
and IL-10 (Figure 1F) was detected compared to cultures with
TMC-TPP particles or sOVA.
No T-cell proliferation or cytokine secretion was induced by
empty nanoparticles (data not shown).
In conclusion, all three OVA loaded nanoparticles enhanced
the antigen presentation by DCs, as shown by increased CD4+ T-
cell proliferation profiles as compared to sOVA.
Nasal vaccination enhances in vivo CD4+ T-cell activation
and differentially induces Foxp3 expression
Next, we questioned whether nanoparticle treatment also affected
CD4+ T-cell responses in vivo. Previously, we showed that especially
TMC-TPP nanoparticles enhanced generation of antigen-specific
IgG1 and IgG2a antibody titers after both i.n. and i.m. vaccination,
encapsulated in nanoparticles. Gray filled histograms; unstimulated CD4+ T-cells, Black overlays; CD4+ T-cell division patterns at different OVA
concentrations after 72 hours. D–F. Cytokine concentrations of IL-2, IFN-c and IL-10 (ng/ml) were determined in culture supernatants, after 72 h of
culture. Data are representative for 3 independent experiments; mean 6 SEM. Statistically significant: *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0026684.g001
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whereas PLGA and PLGA-TMC only resulted in higher IgG titers
after i.m vaccination and had little effect on the humoral immune
response after i.n. treatment [18].
First we studied the short-term CD4+ T-cell response in mice that
were treated i.n. or i.m. with 30 mg of sOVA or OVA encapsulated
particles. Proliferation of OVA-specific CFSE-labeled CD4+ T-cells
was addressed locally in the draining lymph nodes as well as
systemically in the spleen 72 h after treatment (Figures 2A and 2D).
Nasal vaccination induced strong local CD4+ T-cell proliferation
in the nasopharynx-associated lymphoid tissue (NALT) and cervical
lymph nodes (CLN), irrespective of the type of nanoparticle, whereas
low-dose sOVA did not. None of the formulations induced
measurable CD4+ T-cell activation in the spleen at 72 hours after
vaccination upon i.n. immunization (Figure 2A). In contrast, non-
mucosal vaccination resulted in proliferation both in the draining
inguinal lymph nodes (ILN) and spleen at this time point (Figure 2D).
Figure 2. Enhanced OVA-specific CD4+ T-cell proliferation, after nanoparticle administration. A and D. OVA-specific CFSE labeled CD4+
T-cells were transferred to BALB/c recipient mice one day prior to vaccination. Mice received a single i.n. application of 30 mg of sOVA or OVA
encapsulated into PLGA, PLGA-TMC or TMC-TPP nanoparticles. For induction of a non-mucosal response, mice received a single i.m. immunization in
the hind limbs. At 72 h post OVA administration, in vivo T-cell division was addressed in spleen, nose-draining NALT and CLN as well as the thigh-
draining ILN. Data are representative for at least 3 i.n. and 2 i.m. independent transfer studies. B, C and E. Total mRNA was purified from single cell
suspensions from NALT, CLN, and ILN. Relative mRNA expression to HPRT of Foxp3 was determined 72 h post OVA application. Cells isolated from
NALT were pooled per group. LN data are representative for at least 3 to 5 mice per group; mean 6 SEM. Statistically significant: *, P,0.05.
doi:10.1371/journal.pone.0026684.g002
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We did not detect significant differences in cytokine profiles in
culture supernatants of the isolated draining CLN and ILN organs
after particle vaccination (data not shown). However, we observed
an increased expression in the relative Foxp3 mRNA expression in
the CLN (Figure 2C) and a slightly increased expression in the
NALT (Figure 2B) of mice that had received a single i.n. PLGA
vaccination. Mice that were vaccinated i.m. with TMC-TPP
particles showed less expression of Foxp3 mRNA compared to
PLGA and PLGA-TMC treated mice in the ILN (Figure 2E).
These data show that i.n. vaccination with low-dose OVA
encapsulated nanoparticles enhanced CD4+ T-cell proliferation in
contrast to low-dose sOVA treatment (Figure 2A) and coincided
with enhanced Foxp3 mRNA expression in the NALT and CLN
only when PLGA encapsulated OVA was applied (Figures 2B and
2C). This effect was lacking in the i.m. treated mice of all
treatment groups (Figure 2E) showing that, both particle and route
of application determine the outcome of the CD4+ T-cell response.
PLGA nanoparticle vaccination suppressed DTH response
To see if the differences in T-cell response induced after nasal
treatment are of functional importance, the nanoparticles were
tested for immunomodulation in a DTH-model. Mice received
20 mg of OVA i.n. three times at 24 h intervals either dissolved in
PBS or encapsulated in PLGA, PLGA-TMC or TMC-TPP
nanoparticles. Subsequently, mice were sensitized by OVA/IFA
and challenged with OVA in the auricle of the ear. Ear-thickness
was determined 24 h after challenge and compared with measures
before challenge. PLGA nanoparticle treatment suppressed the
OVA-specific DTH response, whereas PLGA-TMC and TMC-
TPP nanoparticles did not (Figure 3A). Non-tolerized mice showed
a strong ear-thickness response comparable to low dose sOVA
(17.4561.44), whereas mice tolerized by high dose sOVA
significantly reduced a DTH response (9.161.21).
In contrast to PLGA and PLGA-TMC, nasal application of
TMC-TPP led to a systemic OVA-specific B-cell response
(Figure 3C) and significantly increased humoral immunity locally
in the draining CLN (Figure 3B). In agreement with earlier studies,
this suggested a role for TMC-TPP in the activation of the
humoral immune response after nasal treatment [18]. In addition,
PLGA-TMC and TMC-TPP nanoparticles seemed to have an
inhibitory effect on IL-10 mRNA expression locally in the draining
CLN, whereas PLGA induced IL-10 mRNA expression did not
differ from sOVA (Figure 3D). Although we detected increased
expression of relative Foxp3 mRNA in the T-cell transfer study
(Figures 2B and 2C) we were not able to detect such differences in
the DTH model, probably due to experimental differences in
timing and the presence of OVA-specific T-cells in the transfer
model.
To summarize, only nasal treatment with PLGA nanoparticles
induced nasal tolerance to a low dose antigen but did not enhance
humoral immunity as shown by the absence of antigen-specific B-
cell responses (Figures 3A and 3B). In contrast to PLGA and
PLGA-TMC immunization, only TMC-TPP treatment led to
activation of humoral immunity as shown by local increased
generation of antigen-specific B-cells (Figure 3B) and increased
antigen-specific antibody titers systemically (see [18]).
Enhanced protection against arthritis after nasal
application of mB29a PLGA nanoparticles
We demonstrated that upon nasal application of OVA-PLGA
nanoparticles, mice were able to suppress a local induced Th-1
mediated inflammatory response in an OVA-specific DTH-model.
Additionally, we investigated whether enhanced nasal tolerance
induction mediated by PLGA treatment was sufficient to suppress
a chronic inflammatory response. Hsp70-peptide mB29a was
encapsulated into each of the nanoparticles and we tested the
capacity of the nanoparticles to modulate the response towards
mucosal tolerance in the PGIA mouse model. Mice were tolerized
by three times i.n. hsp70-peptide treatment either dissolved in PBS
or encapsulated in nanoparticles prior to arthritis induction by two
i.p. PG/DDA immunizations with a three week interval. These
initial data showed proof of principle that treatment with PLGA
nanoparticles reduced mean arthritis scores that lasted up to 30
days after disease development (Figures 4A and 4B), which
correlated with earlier antigen release kinetics studies [18]. As
expected, we did not observe an immunosuppressive function for
TMC-TPP, as the mean arthritis scores (1.260.2) in these mice
were not significantly lower than that of control mice (data not
shown). Furthermore, the lower mean arthritis scores observed
after PLGA or PLGA-TMC treatment coincided with a later onset
of disease and lower maximum arthritis scores (Table 1).
Discussion
In the area of vaccine development, nasal delivery is an
attractive route also given the non-invasive needle-free adminis-
tration [16,32]. Earlier studies already showed that nasal
nanoparticle treatment enhanced humoral immunity [4,18] or
suppressed this by mucosal tolerance induction [24], depending on
the antigen-particle combination. Since there was not much
known about the role of CD4+ T-cells upon nasal nanoparticle
treatment, we explored how nanoparticle treatment affected CD4+
T-cell activation both in vitro and in vivo.
Particle characteristics modulated DC-induced OVA-specific
CD4+ T-cell proliferation in vitro (Figure 1C) since low-dose sOVA
was not able to activate T-cells whereas particle incorporated
OVA had a differential capacity to do so. The proliferative
response was not a result of antigen-independent particle induced
activation since empty nanoparticles were not able to activate T-
cells (data not shown). Although the uptake of sOVA-FITC in
Figure 1A and 1B was more efficient in contrast to TMC-TPP
nanoparticle treatment at various OVA concentrations, the
amount of sOVA was insufficient to activate T-cells in vitro as
shown in Figure 1C. In addition, sOVA-FITC uptake was similar
to that of PLGA and PLGA-TMC at 1 mg/ml concentrations
(Figure 1A and 1B) however it was not sufficient for sOVA to
induce T-cell activation (Figure 1C). Although sOVA treated cells
will also present their antigen via MHC class II we suggested that
the expression of MHC molecules will be maintained for a shorter
period of time in contrast to nanoparticle induced expression as
previously described [33,34]. Here, the authors showed that
PLGA-microspheres in vitro induced prolongation of antigen
presentation by the MHC class I molecule [33,34] and MHC
class II molecule [34] by antigen presenting cells.
Therefore, we suggest that nanoparticle mediated T-cell
activation at similar low OVA concentrations was enhanced due
to differences in MHC class II expression and antigen presentation
in contrast to sOVA and that antigen uptake does not necessarily
need to correlate with T-cell activation (Figure 1).
We showed that low-dose OVA-encapsulated nanoparticles
enhanced OVA-specific CD4+ T-cell proliferation locally in the
NALT and CLN after a single nasal application, which was not
seen with low-dose sOVA. This showed the superiority of
nanoparticle mediated OVA delivery versus sOVA delivery
(Figure 2A). In addition, systemic CD4+ T-cell activation following
nasal treatment requires a longer time frame as compared to non-
mucosal antigen immunization (Figure 2). These data confirm that
Nanoparticles Modulate Nasal Vaccination
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also the route of antigen delivery activates the immune system, as
previously described [23].
Since CD4+CD25+Foxp3+ regulatory T cells play an important
role in the induction of mucosal tolerance [35,36], we explored
Foxp3 expression after nasal nanoparticle treatment. Interestingly,
Foxp3 mRNA expression was increased locally in the CLN, only
after PLGA treatment (Figure 2C) although proliferation profiles
were comparable for all particles (Figure 2A). This suggests that
different nanoparticles induced a differential T-cell response and
only T-cells activated in presence of PLGA nanoparticles obtained
a tolerogenic phenotype as compared to nasal treatment with
PLGA-TMC or TMC-TPP (Figures 2B and 2C).
And indeed nasal treatment with low-dose OVA-encapsulated
PLGA nanoparticles induced a functional immunomodulatory T-cell
response as shown by a reduced DTH response (Figure 3A). We did
not observe a tolerogenic effect in the DTH model when mice were
treated with low-dose sOVA alone. We suggest that this is due to the
low-dose sOVA concentration (3620 mg) that was used for tolerization
of the mice since high-dose sOVA (36100 mg) was sufficient to induce
tolerance (Figure 3A) and ([23,37]). The absence of stimulatory effects
of the low-dose sOVA or OVA incorporated in the nanoparticles on
dendritic cells argues against LPS contamination. Moreover, if our
OVA contained high doses of LPS contamination, high-dose sOVA
would not be expected to suppress a DTH.
Figure 3. Nasal application of PLGA particles suppressed a Th-1-mediated hypersensitivity reaction, while TMC-TPP enhanced
humoral immunity. A. Mice received 20 mg of OVA i.n. either dissolved in PBS (black circles) or encapsulated in TMC-TPP (white circles), PLGA (black
triangles) or PLGA-TMC (white triangles) nanoparticles for three successive days. Mice were sensitized subcutaneously after nasal OVA administration
and subsequently challenged in the auricle of both ears. Changes in ear-thickness were determined and compared with values before challenge. B
and C. OVA-specific B-cell response induced after nasal nanoparticle treatment. OVA-specific B-cell response was assessed by ELISPOT. Data are
shown as the OVA-specific B-cell count per 1*106 cells from CLN and spleen above background (spots counted on medium coated plates). D. PLGA-
TMC and TMC-TPP nanoparticles inhibit IL-10 mRNA expression in the CLN whereas PLGA induced IL-10 mRNA expression did not differ from sOVA.
Relative mRNA expression to HPRT of IL-10 was determined in the CLN of mice. Data are shown as the mean 6 SEM. of n = 5 mice per group.
Statistically significant: *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0026684.g003
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Nevertheless, low-dose sOVA administration might still favor
tolerance induction as shown by the IL-10 mRNA expression in
the draining CLN (Figure 3D) however it might not be strong
enough to actually suppress the inflammatory response.
Interestingly enough, PLGA particles that were capable of
reducing DTH reactivity also had the capacity to induce IL-10
(Figure 3D), suggesting that the characteristics of the PLGA
nanoparticle enhanced tolerance induction in contrast to low-dose
sOVA.
No immunosuppressive reaction was seen in TMC-TPP treated
mice that showed significantly increased OVA-specific B-cells in
the CLN (Figure 3B) but not in spleen (Figure 3C). Although we
were able to detect low titers of total IgG OVA-specific antibodies
in the serum of treated mice, these differences were not significant
(data not shown). We therefore concluded that at this time point
no systemic but only a local OVA-specific B-cell response was
induced in the CLN. In a previous study we explored the effect of
nanoparticle treatment on B-cell activation during a 10-week
vaccination study [18]. Here, nasal treatment with TMC-TPP
nanoparticles resulted in significantly enhanced OVA-specific IgG
titers in serum, in contrast to PLGA and PLGA-TMC treatment.
Moreover, only after nasal vaccination with TMC-TPP nanopar-
ticles, the antibody titers were comparable to those obtained after
i.m. TMC-TPP treatment.
Taken together, these data suggest that upon nasal nanoparticle
application, specifically TMC-TPP nanoparticles activate the
humoral arm of the mucosal immune system (Figure 3B and [18]).
Additionally, we looked at nanoparticle-mediated immunomod-
ulation after nasal application in a chronic inflammatory condition
by using the PGIA model. In various experimental arthritis
models, Hsp(-peptides) were shown to have a capacity to down
modulate arthritis, which seems to be mediated by the induction of
Hsp-specific regulatory CD4+ T-cells [38–41]. Recently, we
uncovered a therapeutic potential for mouse Hsp70-peptide
mB29a to suppress arthritis after nasal application [31].
Here we show that mB29a peptide encapsulation into PLGA
and PLGA-TMC nanoparticles enhanced the tolerogenic capacity
of the peptide. Intranasal treatment with 30 mg of peptide
dissolved in PBS did not reduce the severity of arthritis compared
to encapsulated peptide (Table 1). We have seen that nasal
application of encapsulated antigen can induce a tolerogenic
response not only in a typical Th1 mediated DTH response, but
also in principle in a model of chronic and relapsing arthritis. A
difference in tolerogenic capacity was observed for the PLGA-
TMC particles that suppress PGIA completely (Figure 4), but only
partially suppressed the OVA DTH response (Figure 3A). This
difference can be the result of the nature of the antigen and the
chronic nature of the model itself. Hsp70 in the PGIA model is a
self antigen that is expressed also by immune cells of the host,
thereby enhancing the regulatory T cells induced by the intranasal
treatment. In addition, arthritis is a chronic inflammation in
contrast to the DTH response prolonging the effective window of
the tolerogenic effect of PLGA-TMC treatment.
In conclusion, our results indicate that nasal administration of
antigen by PLGA-containing nanoparticles can enhance an
immunosuppressive response even at a low antigen dose, while
TMC-TPP nanoparticles enhance humoral immunity. As men-
tioned in the introduction both antigen and vaccine characteristic
affect the induced type of the immune response. Our results
Figure 4. Nasal application of low-dose mB29a-PLGA containing particles reduces severity of arthritis. A and B. Effect of mB29a-
nanoparticles on nasally induced suppression of PG-induced arthritis in BALB/c mice. Mice received 30 mg of mB29a peptide i.n. dissolved in PBS or
encapsulated in PLGA or PLGA-TMC nanoparticles prior to arthritis induction. Arthritis scores of mB29a-PBS (black squares), PLGA (black circles) or
PLGA-TMC (black triangles) treated mice as assessed by swelling and redness of the paws. Data are shown as the mean arthritis scores 6 SEM. of n = 3
mice per group. Statistically significant: **, P,0.01.
doi:10.1371/journal.pone.0026684.g004
Table 1. Onset of disease and maximum arthritis scores.




Hsp70-mB29a peptide loaded PLGA, PLGA-TMC nanoparticles or PBS control
(10 mg) were given i.n. on day 27, 25 and 23 and arthritis was induced by PG/
DDA immunization on day 0 and 21. Arthritis symptoms were scored as
described in materials and methods. Day of onset and maximum arthritis scores
were depicted as mean 6 SEM. of n = 3 mice per group of one experiment.
doi:10.1371/journal.pone.0026684.t001
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confirm that particle and antigen combinations need to be
carefully constructed to design successful vaccines that induce
the preferred type of immune response.
These findings may help the development of nanoparticle based
interventions to drive an antigen-specific immunomodulatory
response and will enable future rational vaccine design for
prophylactic and therapeutic vaccination, respectively in infectious
diseases and autoimmune diseases.
Methods
Ethics statement
All mice were kept in our animal facility at the Central Animal
Laboratory (GDL), Utrecht University, The Netherlands under
standard housing conditions. Experiments were approved by the
Animal Experiment Committee of the Utrecht University,
Utrecht, The Netherlands (Permit Number: 2007.II.03.072 and
2009.II.08.075).
Mice
Male BALB/c mice (8–12 weeks) and female BALB/c mice
(retired breeders aged between 16–26 weeks) were purchased from
Charles River Laboratories (Maastricht, The Netherlands). OVA-
specific TCR transgenic (Tg) mice on BALB/c background
(DO11.10 mice), were bred at the Central Animal Laboratory
(GDL), Utrecht University, The Netherlands.
Antibodies and antigen encapsulated nanoparticles
In all in vitro and in vivo experiments, endotoxin-low OVA was
purchased at Calbiochem (San Diego, CA). Murine Hsp70 peptide
mB29a (HspA9-derived sequence VLRVINEPTAAALAY) was
encapsulated into PLGA, PLGA-TMC or TMC-TPP nanoparti-
cles and OVA-encapsulated PLGA, PLGA-TMC and TMC-TPP
nanoparticles were generated as described previously [17,18]. For
detailed information about the particle characteristics such as size,
zeta potential, loading efficiency and the polydispersity index, we
refer to the paper published by Slütter et al. [18]. Anti-DO11.10
TCR (KJ1.26) was purchased from Molecular Probes (Invitrogen,
Breda, The Netherlands), 7-Amino-actinomycin-D (7-AAD)-un-
conjugated, Anti-CD11c (HL3), anti-CD4 (RM4-5), anti-CD40
(3/23), anti-CD86 (GL1), anti-MHC class II (M5/114), antibodies
were purchased from BD Pharmingen (Woerden, The Nether-
lands). Anti-Foxp3-PE (FJK-16s) and an appropriate isotype
control were purchased from eBioscience (Breda, The Nether-
lands)..
DC culture
Bone marrow-derived dendritic cells (BMDC) were cultured
from BALB/c donor mice as previously described with minor
modifications [42]. Briefly, femurs and tibia of adult BALB/c mice
were flushed with culture medium. Single cell suspensions were
seeded in complete Iscove’s Modified Dulbecco’s Medium
(IMDM) supplemented with 561025 M 2-mercaptoethanol,
penicillin (100 units/ml) and streptomycin (100 mg/ml) (Gibco,
Karlsrule, Germany) and 20 ng/ml murine rGM-CSF (Cytogen,
The Netherlands). On day 2 and 4, 10 ng/ml murine rGM-CSF
was added. The cells were cultured in a humidified 5% CO2
atmosphere at 37uC. On day 7, the BMDCs were routinely pure
between 70% and 80% based on CD11c and MHC class II
expression and used for further experiments.
CD4+ T- cell enrichment and CFSE labeling
Spleens were isolated from DO11.10 donor mice and were
prepared into single cell suspensions. CD4+ T-cells were obtained
by negative selection with sheep-anti-rat IgG Dynabeads (Dynal,
Invitrogen, Breda, The Netherlands) using an excess amount of
anti-B220 (RA3-6B2), anti-CD11b (M1/70), anti-MHC class II
(M5/114), anti-CD8 (YTS169) mAb. Enriched CD4+ T-cells were
routinely pure between 85 and 90%. Labeling of cells with
carboxy-fluorescein diacetate succinimidyl ester (CFSE; Molecular
Probes, Leiden, The Netherlands) was performed as previously
described [43].
In vitro effect of nanoparticles on DC
To address maturation of BMDC by nanoparticles, BMDC
were cultured in the presence of PLGA, PLGA-TMC or TMC-
TPP nanoparticles containing 25 ng/ml to 1.0 mg/ml OVA or
10 ng/ml LPS (Sigma) as a maturation control. After 24 h, DC
maturation was determined by flow cytometry (FACS-Calibur; BD
Pharmingen) and FlowJo Software V8.8.6.
BMDCs were incubated for 1.5 hours at either 4uC or 37uC
with FITC-labeled OVA protein purchased from Molecular
probes (Invitrogen, Breda, The Netherlands) dissolved in PBS or
with antigen incorporated into PLGA, PLGA-TMC or TMC-
TPP. To quench external FITC, trypan blue stain (Gibco,
Invitrogen) was added to each sample 5 minutes before FACS
analysis at a final concentration of 0.02% and uptake was analyzed
by flow cytometry. BMDCs were pre-incubated at 37uC for 2 h in
the presence of OVA protein dissolved in PBS or incorporated in
nanoparticles (PLGA, PLGA-TMC or TMC-TPP) at concentra-
tions of 25 ng/ml, 0.5 mg/ml or 1.0 mg/ml. OVA-specific CD4+
T-cells were added at an 1:10 DC:T-cell ratio and T-cell
proliferation was assessed after 72 h by CFSE dilution.
T-cell activation in the local lymph nodes after
nanoparticle vaccination
BALB/c recipient mice were adoptively transferred with 1.107
CFSE-labeled CD4+KJ1.26+ cells in 100 ml PBS, intravenously.
The next day mice received a single application of 30 mg of OVA
dissolved in 10 ml of PBS or encapsulated into PLGA, PLGA-
TMC or TMC-TPP nanoparticles i.n. or intramuscular i.m. in the
hind limbs. 72 h after i.n. or i.m. OVA administration, the spleen,
NALT and CLN as well as the thigh-draining ILN were harvested
and single cell suspensions were analyzed.
Delayed-type hypersensitivity (DTH) reaction
BALB/c mice received 20 mg of OVA i.n. three times at 24 h
intervals either dissolved in PBS or encapsulated in PLGA, PLGA-
TMC or TMC-TPP nanoparticles. Control groups received PBS
alone or OVA at a final concentration of 100 mg in PBS. Mice
were sensitized for a DTH the next day with 100 mg of OVA in
25 ml of PBS, mixed with 25 ml of Incomplete Freund’s Adjuvant
(IFA) (Difco, BD. Alphen a/d Rijn, The Netherlands) subcutane-
ously (s.c.) administered in the tail base. Five days later, ear-
thickness of both ears was measured with an engineer’s
micrometer (Mitutoyo, Tokio, Japan). Subsequently, mice were
challenged with 10 mg of OVA in 10 ml of PBS given in the auricle
of each ear and 24 h post-challenge, the increase in ear thickness
of both ears was determined.
The early B-cell response was assessed by detection of OVA-
specific B-cells of immunized mice by ELISPOT. Single cell
suspensions from the NALT, CLN and spleen were cultured with
OVA (1 mg/well) or control on high protein binding filter plates
(MultiScreen-IP, Millipore) for 48 hours. After incubation, spot
forming units were detected with goat-anti mouse IgG-biotin
(Sigma) and Avidin-AP (Sigma). Plates were developed with NBT-
BCIP (Roche) and analyzed by using the Aelvis spotreader and
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software. Data are shown as the OVA-specific B-cell count per
1*106 cells (antigen-induced-background).
Nasal tolerance induction and assessment of arthritis
Female retired breeder BALB/c mice were treated 3 times with
10 mg of mouse Hsp70- peptide mB29a in PBS or encapsulated
into PLGA, PLGA-TMC or TMC-TPP nanoparticles i.n.
dissolved in 10 ml PBS on days 27, 25, 23. Arthritis was
induced by intraperitoneal (i.p.) injections of 300 mg proteoglycan
(PG) protein with 2 mg of the synthetic adjuvant dimethyl-
dioctadecyl-ammoniumbromide (DDA) (Sigma) emulsified in PBS
(total volume of 200 ml) on day 0 and day 21 as described [44,45].
After the second PG immunization, the onset and severity of
arthritis were determined using a standard visual scoring system
based on swelling and redness of the paws as described [44].
Luminex
CD4+ T-cells isolated from the spleen of DO11.10 mice were
incubated with BMDCs isolated from BALB/c wt mice at an 1:10
DC:T-cell ratio and stimulated with sOVA or OVA encapsulated
in nanoparticles in complete IMDM supplemented with
561025 M 2-mercaptoethanol, penicillin (100 units/ml) and
streptomycin (100 mg/ml) (Gibco, Karlsrule, Germany) at 37uC.
The amount of cytokine secreted after a 72 h T-cell re-stimulation
was assessed by analyzing the culture supernatants. Briefly,
fluoresceinated microbeads coated with capture antibodies for
simultaneous detection of IFN-c (AN18), IL-2 (JES6-1A12), IL-10
(JES5-2A5), (BD Biosciences Pharmingen) were added to 50 ml of
culture supernatant. Cytokines were detected by biotinylated
antibodies IFN-c (XMG1.2), IL-2 (JES6-5H4), IL-10 (SXC-1), and
PE-labeled streptavidin (BD Biosciences Pharmingen). Fluores-
cence was measured using a Luminex model 100 XYP (Luminex,
Austin, TX, USA).
RT-PCR analysis
Total mRNA was purified from single cell suspensions from
NALT, CLN, ILN or spleen using the RNeasy kit (Qiagen
Benelux B.V.) according to the manufacturer’s protocol. RNA was
reverse transcribed into cDNA using the iScriptTM cDNA
Synthesis Kit (Bio-Rad Laboratories, B.V) according to the
manufacturer’s protocol. RT-PCR was performed using a MyiQ
Single-Color RT-PCR detection system (Bio-Rad Laboratories
B.V.) based on specific primers and general fluorescence detection
with SYBR Green (iQ SYBR Green Supermix, Bio-Rad
laboratories, Hercules, CA). Conditions for the Real-time
quantitative reaction were (95uC for 3 min and 40 cycles of
95uC for 10 s and 59.5uC for 45 s). Expression was normalized to
the detected Ct values of hypoxanthine-guanine phosphoribosyl-
transferase (HPRT) for each sample. The expression levels relative
to HPRT were calculated by the equation: relative expression
level = 22DDCt (Livak Method). Specific primers were designed
across different constant region exons resulting in the following
primers:
HPRT sense 59-CTGGTGAAAAGGACCTCTCG-39, anti-
sense 59-TGAAGTACTCATTATAGTCAAGGGCA-39. IL-10
sense 59- GGTTGCCAAGCCTTATCGGA-39, antisense 59-
ACCTGCTCCACTGCCTTGCT-39. Foxp3 sense 59-CCCAG-
GAAAGACAGCAACCTT-39, antisense 59-TTCT CACAAC-
CAGGCCACTTG-39.
Statistics
Statistical analysis was performed with Prism software (Graph-
pad Software Inc., San Diego, version 4.00) using a one-way
ANOVA followed by a Kruskal-Wallis test and Dunn’s multiple
comparison test was used for the in vitro cytokine and FoxP3
mRNA assay and a one-way ANOVA followed by Bonferroni’s
multiple comparison test was used for statistical analysis of the
Delayed-type hypersensitivity reaction. An unpaired two-tailed
Student’s t test was used for statistical analysis in all other
experiments. Error bars represent the S.D. or S.E.M.. as indicated.
Statistical differences for the mean values are indicated as follows:
*, P,0.05; **, P,0.01; ***, P,0.001.
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